<code id='41798463DE'></code><style id='41798463DE'></style>
    • <acronym id='41798463DE'></acronym>
      <center id='41798463DE'><center id='41798463DE'><tfoot id='41798463DE'></tfoot></center><abbr id='41798463DE'><dir id='41798463DE'><tfoot id='41798463DE'></tfoot><noframes id='41798463DE'>

    • <optgroup id='41798463DE'><strike id='41798463DE'><sup id='41798463DE'></sup></strike><code id='41798463DE'></code></optgroup>
        1. <b id='41798463DE'><label id='41798463DE'><select id='41798463DE'><dt id='41798463DE'><span id='41798463DE'></span></dt></select></label></b><u id='41798463DE'></u>
          <i id='41798463DE'><strike id='41798463DE'><tt id='41798463DE'><pre id='41798463DE'></pre></tt></strike></i>

          fashion

          fashion

          author:comprehensive    Page View:69591
          Alnylam headquarters
          Kristoffer Tripplaar/Sipa USA/AP

          Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

          Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

          advertisement

          The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Listen: PBM conflicts, RSV vaccines, & the future of flu season
          Listen: PBM conflicts, RSV vaccines, & the future of flu season

          SammyKimballforSTATWho’swatchingthedrugpricewatchmen?AreRSVvaccinestooexpensive?Andisitfinallytimefo

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          UCLA team creates talking throat patch for voice disorders

          AdobeResearchersattheUniversityofCalifornia,LosAngeles,havebuiltasoft,adhesivepatchcapableofturningt